Coreleader Biotech signed a MOU for co-development of HEMO-bandage with the Chinese Army of Taiwan, Republic of China on Sept. 13th, 2017.  

Dr. Y.C. Wu, Surgeon General, also MD by training with specialty in aviation medicine, compliments the company's technological advance in hemostatic agent development and agrees to support the clinical studies of HEMO-bandage so to build up a data bank with scientific proof. He also expressed his expectation to the developer of the know-how of HEMO-bandage,  The Taiwan Textile Research Institute (TTRI) for the potential cooperation between army and industry to support his team's study on the new wave of biomaterial development for implantation and combat Casualty.   Given their existing establishment, he believes that TTRI would be a new source to refuel the momentum for break-through and of inspiration for the advancement of medical devices related to the textile-based items.    

To echo Surgeon General, Mr. T. Tsao, CEO of Coreleader Biotech assured the commitment of Coreleader's quest for new products.  This is because he believes innovation for differentiation is the best way to reduce the tension from competitors. Mr. Tsao also disclosed their ongoing project for a new hemostatic agent which involves the Missile Research center of Taiwan in addition to the TTRI. Their joint work aims at developing a new fiber which is a mixture of at least two biomaterials for the treatment of coagulopathic patients. Soon the stereotype would be ready for testing. 

All three parties believe the MOU will enable them to work closely and hence, benefit from the synergy derived from the team under Dr. YC Wu's command.